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ABSTRACT
Glucocorticoids (GCs) act through the glucocorticoid receptor (GR,
also known as NR3C1) to regulate immunity, energy metabolism and
tissue repair. Upon ligand binding, activated GR mediates cellular
effects by regulating gene expression, but some GR effects can
occur rapidly without new transcription. Here, we show that GCs
rapidly inhibit cell migration, in response to both GR agonist and
antagonist ligand binding. The inhibitory effect on migration is
prevented by GR knockdown with siRNA, confirming GR
specificity, but not by actinomycin D treatment, suggesting a non-
transcriptional mechanism. We identified a rapid onset increase in
microtubule polymerisation following GC treatment, identifying
cytoskeletal stabilisation as the likely mechanism of action. HDAC6
overexpression, but not knockdown of αTAT1, rescued the GC effect,
implicating HDAC6 as the GR effector. Consistent with this
hypothesis, ligand-dependent cytoplasmic interaction between GR
and HDAC6 was demonstrated by quantitative imaging. Taken
together, we propose that activated GR inhibits HDAC6 function,
and thereby increases the stability of the microtubule network to
reduce cell motility. We therefore report a novel, non-transcriptional
mechanism whereby GCs impair cell motility through inhibition of
HDAC6 and rapid reorganization of the cell architecture.
This article has an associated First Person interview with the first
author of the paper.
KEY WORDS: HDAC6, Cell migration, Glucocorticoid, Microtubule,
Quantitative imaging
INTRODUCTION
Glucocorticoids (GCs) are steroid hormones that regulate a range
of biological functions essential for life, including normal
homeostasis, glucose metabolism, resolution of inflammation
and development (McMaster et al., 2008; Tu et al., 2018; Tanaka
et al., 2017). GCs exert their biological effects through the
ubiquitously expressed glucocorticoid receptor (GR; also known
as NR3C1), a ligand-inducible transcription factor of the nuclear
hormone receptor superfamily (Hollenberg et al., 1985). Synthetic
GCs (including dexamethasone, fluticasone furoate and prednisolone)
are powerful anti-inflammatory and immunosuppressive drugs that are
widely prescribed in the clinic to treat a variety of ailments
(Donn et al., 2007; Smoak and Cidlowski, 2004; Xing et al., 2015).
However, the pleiotropic action of GCs leads to severe off-target
effects that severely limits prolonged clinical use, including
osteoporosis, diabetes and impaired wound healing (Zhou and
Cidlowski, 2005; Abell et al., 2015). For this study, we investigated
the mechanism underlying GC impairment of wound healing and by
extension the inhibition of cell migration, which is implicated in
impaired wound healing (Matsubayashi et al., 2004).
GCs are known to inhibit the migration of various cell types, yet
with an unrecognised mechanism of action (Fietz et al., 2017;
Murakami et al., 1998). Regulation of cell motility has often been
attributed to reorganization and stabilisation of the actin and
microtubule networks (Akhshi et al., 2014; Yumura et al., 2013;
George et al., 2013; DeFea, 2013; Yang et al., 2010). The actin
network generates the propulsive force necessary for front-end
protrusion and rear-end retraction of cells, facilitating cell
movement (Kaverina and Straube, 2011; Ridley et al., 2003). The
actin and microtubule networks can cross-talk, which impacts
persistent cell movement through myosin convergence and focal
adhesion turnover (Wu and Bezanilla, 2018; Schneider and Persson,
2015; Juanes et al., 2017). Cell movement is highly dependent on
the state of microtubule dynamic stability (Pitaval et al., 2017).
Microtubule stability is regulated by acetylation of lysine-40 (K40)
on α-tubulin, with acetylated α-tubulin being most abundant in
stable microtubules (Piperno et al., 1987; Zhang et al., 2003).
Deacetylation of α-tubulin is catalysed by histone deacetylase-6
(HDAC6) and modulation of HDAC6 activity impacts cell
migration by altering the dynamics of the microtubule network
(Hubbert et al., 2002; Zhang et al., 2007; Shi et al., 2015).
Overexpression of HDAC6 increases cell motility by regulating
microtubule-dependent migration (Ridley et al., 2003; Wu and
Bezanilla, 2018). GRs are known to be bound to the cytoskeleton,
which is important to permit rapid ligand-induced nuclear
translocation of the activated GR, among other functions
(Mayanagi et al., 2008; Hong et al., 2011; Fitzsimons et al., 2008;
Dvorak et al., 2004; Akner et al., 1995). In addition, HDAC6
deacetylates heat-shock protein-90 (Hsp90), which is vital for GR
maturation and maintaining the receptor in a ligand-binding state
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(Tao et al., 2018; Ai et al., 2009; Kovacs et al., 2005; Rajapandi
et al., 2000). GR is also reported to physically associate with
HDAC6 in the nucleus (Govindan, 2010; Rimando et al., 2016). We
hypothesised that GCs inhibit cell migration by altering the stability
of the microtubule network via HDAC6, likely through an
inhibitory interaction facilitated by the interconnected substrate
Hsp90.
We now show that GCs act rapidly, and in a non-transcriptional
mechanism, to inhibit cell migration. Furthermore, GCs impair
HDAC6 regulation of the microtubule network to increase the
proportion of short-steps and reduce the proportion of long-steps;
modelled as a change in α-stable distribution parameters. There was
evidence that activated GR impacted the movement of HDAC6 in
target cells, and for cross-coupling of the GR and HDAC6, as shown
with fluorescence cross-correlation spectroscopy (FCCS) but not
co-immunoprecipitation, suggesting a highly dynamic and unstable
interaction between a small proportion of the intracellular HDAC6
pool and the activated GR.
RESULTS
GR agonists and antagonists inhibit cell migration
Dexamethasone (dex), a synthetic GR agonist, potently inhibits the
migration of A549 cells tracked by immunofluorescence imaging of
GFP-labelled histone 2B (H2B) (Fig. 1A), causing a marked
reduction in total displacement (median=141.0 µm) and step length
(median=0.43 µm) compared to vehicle-treated controls (median
total displacement=165.8 µm; median step length=0.52 µm)
(Fig. 1B). There was a significant increase in small step size and
corresponding decrease in large step size typical of inhibited cell
migration, revealing a shift in the cell walk properties (Fig. 1C).
Dex also inhibited A549 cell migration at the population level in
wound healing and chemotaxis assays performed over 48 h (Fig.
S1A,B).
In separate experiments tracking cells using brightfield
microscopy, cell migration was also significantly inhibited upon
treatment with the GR antagonist RU486 (vehicle-treated control
median total displacement=235.5 µm; median step length=2.68 µm
compared to RU486 median total displacement=210.3 µm; median
step length=2.63 µm) (Fig. 1D; Fig. S1C), which was surprising,
and indeed RU486 did not antagonise the inhibitory effect of dex
(Fig. 1D,E). RU486 is a competitive GR antagonist that binds and
induces GR nuclear translocation, but then recruits corepressors,
including NCoRs, to block transcription (Fig. S1D). In A549 cells,
we did not detect statistically significant GR transactivation with
RU486 treatment (Fig. S1D).
The overlapping actions of dex and RU486 on cell migration
suggest a common mechanism of action, but one that requires the
GR, and not the transcriptional regulatory actions of the GR. As the
effects seen were so unexpected, we also tested the requirement of
the GR, using siRNA (Fig. 1F; Fig. S1E), which confirmed the need
for GR (Fig. 1G), a conclusion strengthened by complementation
assays using siRNA-resistant HaloTag-GR (Fig. 1H; Fig. S1E,F). In
addition, scratch wound assays of A549 cells demonstrated the
inhibitory effect of the endogenous GC hydrocortisone in addition
to dex and RU486 on cell migration, suggesting a ligand-dependent
mechanism of action (Fig. S1C).
GCs also inhibit the migration of many other cell types. To test
the broader applicability of our findings we used primary peritoneal
macrophages from GRf/f and LysM-creGRf/f mice (Fig. S1F). The
cells expressing wild-type GR show inhibition of migration upon
GC stimulation, but this inhibitory effect is completely lost in the
GR-null cells.
The α-stable distribution models A549 motion
The distribution of step lengths in vehicle- and dex-treated
conditions (Fig. 1C) showed the distinctive walk pattern
indicative of an α-stable distribution, characterised by four
parameters that describe the stability exponent (α), skewness (β),
scale (γ) and location (δ) (Salas-Gonzalez et al., 2013; Burnecki
et al., 2012). GC treatment reduced median step length, signified by
a left-shift in the frequency distribution curve (measured by a
reduction in δ parameter). α-Stable parameters were derived using
MATLAB, showing that A549 cell movement adopted an α-stable
distribution irrespective of GC treatment (Fig. S2A,B). These
changes in parameters show that the movement of vehicle-treated
A549 cells primarily consists of small steps occasionally
interspersed with larger relocating or searching steps. GC alters
these parameters inhibiting the low frequency, large displacement
searching movements.
Synthetic selective GR ligands exhibit similar effects to
conventional GC
In view of the inhibitory effect of RU486 on cell migration, the study
was extended to further non-steroidal GR ligands with unique
pharmacological properties (Trebble et al., 2013; Schiller et al., 2014),
and we selected a panel based on high affinity and specificity
(Fig. 2A). For example, GRT7 extends into the meta channel of the
GR ligand-binding domain (LBD) driving slower kinetics of
activation, but more-potent transcriptional induction (Fig. 2B–D)
(Trebble et al., 2013). GW870086X (086X), is a selective GR
modulator (SeGRM), deficient in transactivation function (Fig. 2D).
All the GR ligands tested similarly reduced A549 cell displacement
(Fig. 2E), affecting both total displacement (086X=188.5 µm;
vehicle=208.3 µm) (GRT7=208.3 µm; vehicle=224.1 µm) and
median step length (086X=2.28 µm; vehicle=2.58 µm)
(GRT7=1.95 µm; vehicle=2.44 µm). Cell walk properties were
similarly inhibited (Fig. 2F,G; Figs S2C–E, S3E,F). As with dex,
RU486 did not antagonise the inhibition of cell migration with GRT7
or O86X (GRT7+RU486 median total displacement=192.6 µm;
GRT7+RU486 median step length=1.86 µm; 086X+RU486
median total displacement=201.3 µm; 086X+RU486 median step
length=2.26 µm). In the study with GRT7, we did see a slight
potentiation of the inhibitory effect when RU486 was added to the
GRT7 compound, but in this series of studies the RU486 effect was
slightly less than seen in other repeats when we analysed total cell
displacement. However, the reduction in median step length was
striking, and consistent throughout. Additional analysis was
conducted using the high potency, steroidal GR agonist fluticasone
propionate (FP), with similar effects on movement (Fig. S3A–C) and
α-stable distribution parameter changes confirming altered walk
properties (Fig. S3D–F).
GC inhibits migration independently of gene transcription
Through dynamic cell tracking (Fig. S1C), we noted that the GC
effect had a rapid onset, an observation not identified previously
using fixed end-point assays (Fig. S1A,B). When we analysed
displacement at earlier time points there was a significant reduction
by 12 h, and a trend was seen even by 4 h, although this did not
reach significance (Fig. S4A–C). To investigate the time course of
the GC response in greater detail, we used a non-parametric rank-
sum test to determine the earliest time-point at which cell migration
was significantly reduced following treatment with each GC and
compared this to the dynamics of ligand-induced GR nuclear
translocation (Fig. 3A–C). Dex and RU486 both inhibited migration
within 60 min of administration; and GRT7, which does not lead to
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translocation of the GR until 3 h post treatment, also inhibits
migration by 60 min. O86X, which induces the most rapid GR
translocation, only inhibits migration after 5 h (indicated by the
coloured arrows, Fig. 3C). The kinetics of nuclear translocation
were inverse to those for migration inhibition. The rapid onset of
action, with response preceding nuclear translocation, as in the
case of the GRT7 ligand, suggested a non-conventional
mechanism of action, such as a cytoplasmic, non-genomic
circuit. A non-conventional mechanism of action is also
supported by the lack of antagonism seen with the use of RU486
in the presence of the agonists, despite the absolute requirement
for the presence of the GR.
Fig. 1. See next page for legend.
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In order to test the importance of new gene transcription for the
altered cell migration we used actinomycin D pre-treatment. A 1-h
treatment with actinomycin D was enough to block the
transcriptional activation function of the GR (Fig. S5A), and these
studies again confirmed the complete lack of agonist activity seen
with RU486 in these cells, under these conditions. Under these
treatment conditions, we were able to see the same change in cell
migration with a 4-h incubation with dex both with and without
actinomycin D blockade of gene transcription (Fig. 3D).
Actinomycin D did not affect cell migration independently.
We also profiled changes in gene expression of a panel of genes
known to control cell migration. In this study, we again selected the
4-h time point as the most discriminating, as the change in cell
migration by this point does not require a change in gene expression.
Here, we observed only two genes (PLAUR and BCAR1) to be
downregulated by a 4 h incubation with dex. This repression was
opposed by RU486, as expected for a conventional GR antagonist.
As GR agonist and antagonist regulated these two genes in opposite
directions, this implies that they are not relevant to the migration
phenotype we are observing, as we show that no new gene
transcription is required for the effect, and also that the migration
phenotype is both observed with RU486 treatment, and also that
RU486 treatment does not oppose the actions of agonists, such as
dex, when the cell migration phenotype is observed (Fig. 3E).
GC treatment rapidly stabilises microtubules
To investigate the mechanism explaining the early onset, non-
transcriptional response of cell migration to GC treatment, we
profiled the activation status of a panel of candidate proteins
(Fig. 4A). We observed a reduction in phosphorylated ERK1/2
(phospho-ERK; ERK1 is also known as MAPK3 and ERK2 as
MAPK1), and an induction in phosphorylated ezrin, radixin and
moesin (phospho-ERM), but these changes were not seen until 24 h
post GC stimulation. This suggests that these molecules are not
involved in mediating the very rapid responses we see in response to
GC treatment, and their change in status may follow on from rather
than drive the change in cell phenotype. To analyse rapid responses,
we turned to live-cell imaging of the cytoskeleton, to determine
whether changes in cytoskeletal architecture could be observed.
To investigate the actin and MT cytoskeletal networks we
examined the effect of dex on MT dynamics by following an GFP-
tagged MT plus-end (+TIP) binding protein, EB3 (also known as
MAPRE3) (Fig. 4B). GC drives an increase in overall MT growth
speed (vehicle median=17.2 μm/min; dex median=17.7 μm/min),
consistent with stabilisation of microtubules (Fig. 4C, total). To
analyse the impact of GCs on MT dynamics in more depth, the
growth speed data was subdivided into thirds, designated slow,
medium and fast (Fig. 4C,D). Dex resulted in an increased median
speed (vehicle=26.2 μm/min; dex=27.6 μm/min) in the fast speed
events, with a decreased speed (vehicle=11.1 μm/min,
dex=10.8 μm/min) observed in the slow speed events, while no
significant difference was detected at medium speed (Fig. 4C). This
indicates a shift to more rapidly polymerising microtubules in the
presence of dex. A concomitant increase in the frequency of fast
growth speed events was also detected (Fig. 4D, 40 μm/min
onwards). We attempted direct measurement of acetylation of α-
tubulin, a marker of microtubule (MT) stability. We did see small
increases at early time points (<10 min), but the effect size was
small, and on further investigation the effect was not robust in
replication. Therefore, we do not have convincing evidence that
tubulin acetylation changes in response to GC, but the changes in
microtubule growth were very robust and highly significant.
GC alter microtubule dynamics by inhibiting HDAC6
Acetylation of tubulin is tightly controlled by the α-tubulin
acetyltransferase αTAT1 and the tubulin deacetylase HDAC6,
making these two enzymes candidate effectors. We examined
αTAT1-knockdown cells (Fig. 5A), but found no effect, suggesting
an alternative mechanism of GR action (Fig. 5B). Tubacin, a
selective HDAC6 inhibitor, not only mimicked the inhibitory effect
of dex (Fig. 5C), but also showed no additive effect in co-treatment
protocols, suggesting a convergent mechanism of action. Therefore,
Fig. 1. GR agonists and antagonists inhibit cell migration. (A–C) Cell
migration data for A549 cells that were transiently transfected with 0.5 µg
pBOS-H2B-GFPand incubated for 24 h at 37°C/5%CO2 prior to imaging. Cells
were treatedwith vehicle (Veh; DMSO) and dexamethasone (dex; 100 nM) and
images acquired every 5 min for 48 h. Data displayed represents the first 24 h
of tracking. (A) Rose plots of A549 cell displacement (µm) in response to 24 h
of vehicle and dex (100 nM) treatment. Each coloured line represents the
displacement of one cell from its point of origin. Each rose plot is representative
of 20 randomly chosen A549 cells. (B) Violin plots of total displacement (µm;
the overall distance moved by every cell tracked) and median step length (µm;
the median of all the distances move by a cell between each image acquisition
over the entire duration of tracking) for A549 cells in response to 24 h of vehicle
and dex (100 nM) treatment. Migration data is representative of 52 individual
cells for vehicle treatment and 54 individual cells for dex treatment, across two
independent experiments. Dashed lines represent the median±interquartile
range (IQR) (unpaired t-test; ****P<0.0001). (C) Frequency distribution curves
of all A549 cell step lengths (µm) in response to 24 h of vehicle and dex
(100 nM) treatment. (D,E) Cell migration data for A549 cells that were tracked
using brightfield microscopy. Cells were treated with vehicle (DMSO) and dex
(100 nM) and images acquired every 10 min for 24 h, with data displaying all
24 h of tracking. (D) Violin plots showing the total displacement (µm) and
median step length (µm) of A549 cells in response to 24 h of vehicle, dex
(100 nM), RU486 (100 nM), and dex+RU486 (both 100 nM) co-treatment.
Migration data is displayed as the median±IQD and represents all cells
analysed over three independent experiments (Kruskal–Wallis non-parametric
test followed by Dunn’s multiple comparisons test; *P=0.0342, **P=0.0076,
****P<0.0001). (E) Rose plots of A549 cell displacement (µm) in response to
24 h of dex (100 nM), RU486 (100 nM), RU486 (100 nM), and a dex+RU486
(both 100 nM) co-treatment. Each coloured line represents the displacement of
one cell from its point of origin. Each rose plot is representative of 20 randomly
chosen A549 cells. (F) Western blot of GR and GAPDH protein expression in
control (non-silencing siRNA-treated) and GR knockdown (GR siRNA#6-
treated) A549 cells in response to 1 and 4 h of vehicle and dex (100 nM)
treatment. siRNA treatments were performed over 48 h. Western blot image is
representative of two independent experiments. (G) Cell migration data for
A549 cells that were tracked using brightfield microscopy. Cells were
transiently transfected with siRNA targeting GR or a non-targeting siRNA
negative control for 48 h. GR-knockdown cells were then treated with vehicle
(DMSO) or dex (100 nM) and images acquired every 10 min for 6 h, with data
displaying all 6 h of tracking. Violin plots of total displacement (µm) andmedian
step length (µm) of control and GR knockdown A549 cells in response to 6 h of
vehicle and dex (100 nM) treatment. Migration data shown asmedian±IQD and
represents all cells analysed over three independent experiments (Kruskal–
Wallis non-parametric test followed by Dunn’s multiple comparisons test;
****P<0.0001). (H) Cell migration data for A549 cells that were tracked using
fluorescence microscopy based on Rhodamine expression. GR-knockdown
cells were transiently transfected with HaloTag empty vector (2 µg) or
HaloTag–GR (2 µg) for 24 h and then treated with vehicle (DMSO) or dex
(100 nM) for 24 h. Cells were labelled overnight with HaloTMRDirect ligand
(100 nM) that labels HaloTag proteins with the Rhodamine fluorophore.
Images were acquired every 10 min, with data displaying 24 h of tracking.
Violin plots of total displacement (µm) and median step length (µm) of control
and GR knockdown A549 cells overexpressing 2 µg empty-pHaloTag control
or 2 µg HaloTag-GR in response to 24 h of vehicle or dex (100 nM) treatment.
GR knockdown was siRNA-mediated over 48 h, alongside a non-silencing
siRNA negative control. Migration data as the median±IQD and represents all
cells analysed over three independent experiments (Kruskal–Wallis non-
parametric test followed by Dunn’s multiple comparisons test; *P=0.0159,
****P<0.0001). ns, not significant.
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we analysed the effect of augmenting HDAC6 expression (Fig. 5D),
which increased both the displacement and median step length of
cells and rendered cells resistant to GC (Fig. 5E,F). The α-stable
distribution parameters changed in response to HDAC6
overexpression with cells adopting a higher proportion of large
walk steps indicating increased cell migration relative to the
controls, which was unchanged following administration of dex
(Fig. 5G,H). The pan-HDAC activator ITSA1 (Haggarty et al.,
2003) also reversed the GC migration phenotype, confirming the
contributory role of HDAC6 in this mechanism (Fig. 5I).
GR and HDAC6 are complexed together in the cytoplasm
There was no evidence of altered HDAC6 subcellular trafficking in
response to dex with the enzyme remaining predominantly
cytoplasmic (Fig. S6A). Co-immunoprecipitation studies also
failed to identify GR and HDAC6 in complex together (Fig. S6B),
Fig. 2. See next page for legend.
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despite previous reports of co-binding and interactive function on
gene repression in the nucleus (Rimando et al., 2016; Govindan,
2010). However, we did detect a change in HDAC6 interactions with
actin components of the cytoskeleton in response to GC (Fig. S6C,
D); although these correlative studies do not provide evidence
for physical, or functional interaction, they do suggest molecular
proximity.
To study the GR–HDAC6 interaction in further detail, we
employed real-time fluorescence cross-correlation spectroscopy
(FCCS), which is able to discriminate between cellular
compartments (marked by crosses, Fig. 6A). We identify a
cytoplasmic but not nuclear interaction between GR and HDAC6 as
compared to an empty fluorophore negative control (Fig. 6B–F). An
approximate 5-fold increase in interaction strength post dex treatment
after GR ligand activation was estimated through determination of
in vivo dissociation constant (Kd) values (Fig. 6G–J).
DISCUSSION
Although therapeutic GCs are widely used, their diverse actions
limit long-term safety. Multiple candidate mechanisms of action
have been advanced, with the major focus on how the same
activated receptor can both repress and activate different genes in a
cell-type-specific context. Gene repression has been a focus of
study, as this pathway appears to mediate the beneficial anti-
inflammatory and immune suppressive actions of GCs
(Ramamoorthy and Cidlowski, 2016). To this end, new partial
agonist GR ligands have been developed and tested in the clinic.
Such selective GR modulators (SeGRMs) differentiate GR function
mainly by affecting the ligand-bound GR conformation, and thereby
recruitment of co-modulators (Caratti et al., 2015). However, GR
can also affect other cellular processes through a non-transcriptional
pathway, for example mitotic spindle function (Matthews et al.,
2011). One major and consistent effect of GC treatment is loss of
tissue integrity, and impaired wound healing. In part, this results
from reduced epithelial, macrophage and fibroblast migration
(McDougall et al., 2006; Hardman et al., 2005). This programme
has not received much attention, but may serve as a model to
understand the distinct actions of GCs. Therefore, we used an
epithelial cell model to measure migratory responses to GC.
Our initial studies sought to mathematically model the walk
properties of cells under basal conditions, to provide a solid baseline
for GC comparison. Our cell walk characteristics fitted an α-stable
distribution, and the impact of GC altered the parameters in such a
way that longer steps were selectively reduced in favour of shorter
steps, thereby impairing the searching behaviour of cells. This real-
time, individual cell tracking permitted the kinetics of response to be
measured, and here the surprising finding was the very rapid onset
of action with significant deviation from control cells within 40 min
of treatment. This rapid onset of action was similarly seen with the
GR antagonist RU486 and with further non-steroidal ligands. That
RU486 failed to oppose the agonist effects raised a question of
specificity, which was addressed in siRNA studies in epithelial
cells, and by replicating the migration assay in macrophages, which
permitted genetic loss of GR to be tested. The rapid onset of effect,
and paradoxical full agonist phenotype seen with RU486, suggested
an unconventional mechanism of action, which was supported by
showing that no new mRNA synthesis is required. Although we
have previously detected inhibition of Rac1 activity soon after GC
treatment in podocytes, in that study wewere unable to establish that
the Rac1 effect was required for the GC effect, and the time for a
Rac1 inhibitor to reduce cell movement was prolonged (>10 h), and
also strikingly different to that seen with GC exposure (McCaffrey
et al., 2017). For these reasons we did not pursue a role for Rac1 in
the current work. Here, we also employed selective GR ligands with
well-characterised differences in GR nuclear translocation kinetics
in order to gain further insights into mechanism of action. We
showed that rapid nuclear translocation did not associate with rapid
inhibition of migration, but rather a GR ligand with a markedly slow
GR translocation rate was still able to affect cell migration rapidly,
even while predominantly residing within the cytoplasm. This is
consequently a well-documented model of a truly non-genomic
mechanism of GR action.
In pursuit of the mechanism of action for rapid changes in cell
motility induced by GR activation, we analysed changes in the
cytoskeletal architecture, using real-time imaging of microtubule
growth. Microtubule kinetics are inverse to cell migration velocity,
with increased microtubule polymerisation making cells less able to
change conformation, and to migrate. We selected a 4-h time
exposure to analyse microtubule polymerisation, as we had shown
that by this time point significant changes in cell migration were
seen, and there were no changes in gene transcription that could
plausibly affect cell migration and, as well as that, blockade of new
gene transcription had no impact on the GC effect. Microtubule
polymerisation is driven by increased tubulin acetylation (Hubbert
et al., 2002; Boggs et al., 2015; Zhang et al., 2003). Tubulin
acetylation is tightly controlled by the opposing actions of the α-
tubulin acetyltransferase αTAT1 and the deacetylase HDAC6
(Castro-Castro et al., 2012; Liu et al., 2012). HDAC6 is localised
predominantly in the cytoplasm, where it directly interacts with
microtubules and catalyses tubulin deacetylation along the length of
the microtubule track (Asthana et al., 2013; Miyake et al., 2016).
Moreover, HDAC6 has shown to prefer deacetylation of tubulin
dimers over polymerized microtubules (Skultetyova et al., 2017).
Here, we show that a non-conventional GR mechanism of action
is responsible to the rapid onset of cell migration inhibition. We also
see the same mechanism at play at later time points, with RU486
failing to inhibit the migratory phenotype even up to 24 h. It is hard
Fig. 2. Selective glucocorticoids also inhibit cell migration. (A) 3D
chemical structures of dex, RU486, GRT7 and GW870086X (086X).
(B) Crystal structures of the GR ligand-binding domain (LBD) bound to dex with
trigger region annotated. (C) Crystal structure of the GR LBD bound to GRT7
annotated with regions altered by ligand-binding (meta channel).
(D) Luciferase activity of the MMTV-luciferase or NRE-luciferase reporter
genes which were transiently transfected into A549 cells over 24 h. Luciferase
activity was monitored after 24 h treatment with vehicle, dex (red), GRT7
(brown), and 086X (blue). Data (RLU) are shown as mean±s.e.m. (n=3).
Ligand potencies are displayed as mean±s.d. IC50 and EC50 values. (E,F) Cell
migration data for A549 cells that were tracked using brightfield microscopy.
Cells were treated with vehicle (Veh; DMSO), GRT7 (100 nM), GW870086X
(100 nM) and RU486 (100 nM), and images acquired every 10 min for 24 h,
with data displaying all 24 h of tracking. (E) Rose plots of A549 cell
displacement (µm) in response to 24 h potency-matched vehicle, RU486
(100 nM), GRT7 (3 nM) and 086X (100 nM). Each coloured line represents the
displacement of one cell from its point of origin. Each rose plot is representative
of 20 randomly chosen A549 cells. (F) Violin plots of total displacement (µm)
andmedian step length (µm) of A549 cells in response to 24 h of vehicle, 086X
(100 nM), RU486 (100 nM), and 086X+RU486 (both 100 nM) co-treatment.
Migration data shown as median±interquartile range (IQR; dashed lines) and
represents all cells analysed over three independent experiments (Kruskal–
Wallis non-parametric test followed by Dunn’s multiple comparisons test;
**P=0.0015, ****P<0.0001). (G) Violin plots of total displacement (µm) and
median step length (µm) of A549 cells in response to 24 h of vehicle, GRT7
(3 nM), RU486 (100 nM), and GRT7+RU486 (both 100 nM) co-treatment.
Migration data shown as median±IQR and represents all cells analysed over
three independent experiments (Kruskal–Wallis non-parametric test
followed by Dunn’s multiple comparisons test; ***P=0.0001, ****P<0.0001).
ns, not significant.
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to exclude the involvement of additional mechanisms of action at
later time points, as with all studies of GC action, the longer
exposures result in a greater number of responses, as secondary and
tertiary events come into play. We cannot block gene transcription
for long periods of time as this is toxic to the cells, and therefore
makes the cellular phenotype hard to interpret, but we can use the
RU486 to block transcriptional activity of the GR. In these cells, and
under these conditions, RU486 is essentially without any agonist
activity. RU486 alone exerts a similar impact on cell migration as
that of the full agonists, identifying a non-transcriptional
mechanism of action.
The GR rapidly translocated to the nucleus after addition of GC,
but despite its mainly nuclear location there is evidence for very
rapid cycling on and off recognition sites in DNA, and shuttling
between the cytoplasm and nucleus, so providing an explanation for
persisting engagement with the HDAC6 enzyme. We observed
GR–HDAC6 interaction in our FCCS studies, which showed
cytoplasmic interaction 1 h after ligand addition, when bulk GR is
Fig. 3. See next page for legend.
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mainly nuclear (Paakinaho et al., 2019). Therefore, taken together,
we have evidence of an unconventional mechanism of GR action
that does not involve target gene transactivation. We do, however,
find a novel interaction between the activated GR and HDAC6, and
show that the HDAC6 is required to mediate the GC effect.
Our studies identify a previous unrecognised mechanism of GR
action with involvement of a protein–protein interaction circuit
targeting HDAC6. We were able to show that the HDAC6
dependence of the GC loss of long-step length migration and the
rapid cellular response, coupled with a lack of requirement for
new gene transcription pointed to a direct mechanism of action with
a pathway connecting activated GR and the HDAC6 protein.
We were not able to show HDAC6–GR interaction by
co-immunoprecipitation, but FCCS studies identified a fraction of
the cytoplasmic HDAC6 pool as interacting with GR, with resultant
changes in movement kinetics, implying a change in molecular
complex formation. The unique cytoplasmic preference for GR
amongst the nuclear receptors may explain its capacity to interact
with cytoplasmic enzymes, such as HDAC6. Our data support a
GR-driven change in HDAC6 behaviour as the mechanism
explaining rapid-kinetic loss of cell movement in response to GC
exposure.
Defective cell migration in response to GC has widespread
consequences including defective tissue repair, and loss of barrier
function. Identification of a new mechanism of GC action has
implications for attempts to design novel GR ligands, with reduced
off-target effects, but also the screening for potent GR ligands
capable of engaging this pathway to treat exuberant wound-healing,
such as keloid.
The identification of a coherent non-genomic GR mechanism of
action leading to a clinically relevant cell migratory phenotype
offers new insight into the diversity of GC action. This pathway
underlines the difficulty in developing specific anti-inflammatory
GR ligands, exemplified by identical action of GR antagonists and
agonists on cell migration. In addition, the inhibition of epithelial
cell migration is also observed in macrophages, providing a new
insight into the anti-inflammatory and immune suppressive
functions of GCs, which have largely been focused on chemokine
production, adhesion molecule expression, cell survival and
enzyme production. Taken together, we elucidate a newly
discovered non-genomic pathway of GC action affecting cell
migration, with proximal impacts on tissue integrity, repair, and
innate immune function.
MATERIALS AND METHODS
Mouse models
Colonies of LysM-GR−/−, mice were maintained in the University of
Manchester Biological Services Facility (BSF) with the Home Office
license PPL 70-8768. All genetically modified mice were created on a
C57BL/6 background and housed in 12 h:12 h light/dark (L:D) cycles with
food and water supplied ad libitum. All protocols were approved by the
University of Manchester Animal Welfare and Ethical Review Body and the
Animals (Scientific Procedures) Act 1986 UKHome Office guidelines were
strictly adhered to. Conditional targeted cre positive mice, were sex and age
matched with floxed/floxed littermate controls; females aged 10-14 weeks
were used for in vivo experiments and PECs for ex vivo were harvested.
Genotyping was performed on all experimental animals.
Cell culture
Human lung epithelial carcinoma (A549) and human cervical
adenocarcinoma (HeLa) cells (ATCC, Teddington, UK) were cultured in
high glucose (4500 mg/l) Dulbecco’s modified Eagle’s medium (DMEM;
D6429, Sigma) with L-glutamine, sodium bicarbonate, sodium pyruvate
and supplemented with 10% heat-inactivated foetal bovine serum (FBS;
F9665, Invitrogen, Paisley, UK) or 10% charcoal-stripped fetal bovine
serum (cFBS; #12676029, Invitrogen, Paisley, UK) at 37°C in 5% CO2.
Antibodies and reagents
Antibodies used were: rabbit polyclonal anti-GR (24050-1-AP) used at
1:1000 dilution for western blots, purchased from ProteinTech; monoclonal
mouse anti-phospho-EzrinThr567, radixinThr564 and moesinThr558 (#3141)
used at 1:1000 dilution for western blots, monoclonal rabbit phospho-
SrcTyr416 (#6943) used at 1:1000 dilution for western blots, monoclonal
rabbit GAPDH (#2118) used at 1:2500 dilution for western blots,
monoclonal rabbit anti-phospho-AktSer473 (#4060) used at 1:1000 dilution
for western blots, and monoclonal rabbit acetyl-α-TubulinLys40 (#5335)
used at 1:1000 dilution for western blots and 1:200 dilution for
immunofluorescence, purchased from Cell Signaling Technology;
onoclonal mouse anti-α-tubulin (T5168) used at 1:5000 dilution for
western blots and 1:500 dilution for immunofluorescence purchased from
Sigma; and polyclonal rabbit anti-αTAT1 (HPA046816) used at 1:100
dilution for immunofluorescence, purchased from Atlas Antibodies. Mouse
IgG horse radish peroxidase (HRP)-linked whole antibody (NXA931) and
rabbit IgG HRP-linked whole antibody (NA934) were purchased from GE
Healthcare both used at 1:2500 dilution for western blots.
Plasmids used were N1-HDAC6-eGFP and GRα-GFP (Addgene
#47504); the N1-HDAC6-eGFP plasmid was constructed by amplifying
the cDNA of human HDAC6 from the plasmid pcDNA3.1(+)-flag-HDAC6
(Addgene #13823) and cloning into the pEGFP-N1 vector (Clontech
#6085-1) using a QuikChange site-directed mutagenesis kit (Agilent
Technologies,. La Jolla, CA, USA). All constructs were verified through
sequencing HaloTag-HDAC6, HaloTag-GR (FHC10483), and pHaloTag
vector were purchased from Promega. pBOS-H2B-GFPwas purchased from
BD Biosciences.
siRNAs used were AllStars Negative Control siRNA (SI03650318), GR
siRNA (SI02654764), and αTAT1 siRNA (S104145162) purchased from
Qiagen.
Reagents used for cell treatments were Rhodamine–phalloidin (R415),
purchased from Invitrogen; dexamethasone (dex, D4902), mifepristone
(RU486, M8046), nicotinamide (N3376), tubacin (SML0065), TSA
(T8552), fluticasone propionate (FP, F9428), Hoechst 33342 (#14533)
and DMSO (D2650) purchased from Sigma; ITSA1 (CAS 200626-61-5)
purchased from Santa Cruz Biotechnology and HaloTag TMRDirect ligand
Fig. 3. Ligand-specific regulation of migration kinetics. (A) Representative
widefield images of HaloTag–GR nuclear accumulation in A549 cells over 6 h of
dex (100 nM), RU486 (100 nM), GRT7 (3 nM), and 086X (100 nM) treatment.
A549 cells were transiently transfected with 250 ng HaloTag–GR and labelled
with Halo®TMRDirect™ ligand (100 nM). Images are representative of three
independent experiments. (B) Nuclear:cytoplasmic ratio of GR localisation in
response to potency-matched treatment of dex (100 nM), RU486 (100 nM),
GRT7 (3 nM) and 086X (100 nM) over 8 h. GR localisation was quantified using
ImageJ. (C) Non-parametric rank-sum test of A549 cell migration (cumulative
distance) signifying the earliest timepoint (coloured arrows) at which migration is
statistically different [P<0.05; Mann–Whitney U (Wilcoxon rank sum) test] in
response to dex (100 nM), RU486 (100 nM), GRT7 (3 nM), and 086X (100 nM)
compared to vehicle-treated controls. (D,E) Cell migration data for A549 cells that
were tracked using brightfield microscopy. Cells were pre-treated for 1 h with
vehicle (DMSO) or actinomycin D (1 µg/ml) before treating with vehicle (DMSO)
or dex (100 nM), and images were acquired every 10 min for 4 h, with data
displaying all 4 h of tracking. (D) Violin plots of total displacement (µm) and
median step length (µm) of A549 cells in response to 1 h pre-treatment with
vehicle or actinomycin D (1 µg/ml) and subsequent 4 h treatment with vehicle or
dex (100 nM). Migration data shown as the median±interquartile range (IQR;
dashed lines) and represents all cells analysed over two independent
experiments (Kruskal–Wallis non-parametric test followed by Dunn’s multiple
comparisons test; *P=0.01, **P<0.004, ***P=0.0001, ****P<0.0001). (E) RT2
qPCR array of genes that regulate cell migration in response to 4 h of dex
(100 nM), and a dex plus RU486 (both 100 nM) co-treatment. Each data point
represents an individual gene. Values on the scatter plot represent log10
(normalised expression). Genes in black have a fold change over the vehicle
control less than 2 and greater than 0.5. Genes with a fold change less than 0.5
(downregulated) are indicated in blue.
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Fig. 4. Glucocorticoids stabilise themicrotubule network. (A)Western blot of total GR, phospho-SrcY416, phospho-AktS473, phospho-EzrinT567/RadixinT564/
MoesinT558 (E/R/M), phospho-caveolinY14, phospho-cortactinY421, phospho-ERKT202/Y204 and total α-tubulin protein expression in response to dex (100 nM)
as a time series (0, 10 min, 30 min, 1 h, 2 h, 4 h, 6 h, and 24 h). Western blots are representative of three independent experiments. (B) Representative
images of A549 cells transiently transfected with EB3–GFP over 24 h and then treated with vehicle (Veh; DMSO) and dex (100 nM) for 4 h. Cells were selected
at random based on expression of EB3–GFP and then microtubule comets (microtubule plus-ends expressing EB3–GFP) were imaged every 0.5 s for 60 s
(total 120 images acquired; top panel). Microtubule dynamics were determined from the 60 s EB3–GFP time series using plusTipTracker software
(MATLAB; middle and bottom panels). Fluorescently labelled microtubule plus-ends were first detected (middle panel) and then microtubule growth events
were tracked (bottom panel), and dynamics determined. Tracks are represented by a colour-coded heat map (indicating growth speed μm/min) imposed upon
the raw image (bottom panel). (C) Violin plots of microtubule growth speed (µm/min) in A549 cells following a 4 h vehicle and dex (100 nM) treatment.
Growth speed data is shown entirely (upper left panel; total) or split into tertiles according to speed (designated slow, medium or fast). Each bin size
corresponds to one-third of all growth speed events following vehicle treatment, and was applied to the dex-treated data set. Data is representative of three
independent experiments (n=3); 9149 (vehicle-treated) and 9669 (dex-treated) growth events, from 10 cells per condition were tracked and analysed. Results
are median±interquartile range (dashed lines; Mann–Whitney non-parametric test; ***P=0.0002, ****P<0.0001; ns, not significant). (D) Histograms displaying
the frequency of microtubule growth speeds (µm/min) in A549 cells following a 4 h vehicle and dex (100 nM) treatment. Growth speed data is shown
entirely (upper left panel; total) or split into tertiles as described in C. Data for vehicle-treated cells is indicated by red bars and for dex-treated cells by
blue bars.
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(G2991) was purchased from Promega. GRT7 and GW870086X were
developed by GlaxoSmithKline. Unique materials used are available from
the authors or from standard commercial sources outlined above.
Chemotaxis migration assay
The chemotaxis migration assay was performed in 24-well Millicell hanging
cell culture inserts (Millipore, MCEP24H48) with an 8 µm polyethylene
terephthalate membrane pore. A549 cells were pre-conditioned to 100 nM
dex or vehicle control (DMSO) for 48 h (37°C/5% CO2). Cells were
suspended in serum-free DMEM and seeded into the upper chamber of the
Transwell insert (2.5×104 cells/well). The lower chamber was filled with
FBS to act as the chemoattractant. 100 nM dex or vehicle control was
added to the upper and lower compartments of the Transwell. The cells are
incubated for 24 h (37°C/5% CO2) to allow chemotaxis to occur.
Fig. 5. See next page for legend.
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Following incubation, the cells were fixed in 4% paraformaldehyde (PFA)
for 15 min at room temperature. Any cells that did not migrate were
removed from the upper side of the membrane with a cotton swab. Cells are
stained with Crystal Violet (5 mg/ml in 2% ethanol) for 30 min at room
temperature. The inserts were washed twice in distilled H2O and excess
stain was removed mechanically from the upper side of the membrane. The
migrated cells were solubilised in 2% SDS overnight at room temperature
and absorbance was read at 560 nm using a Glomax plate reader
(Promega). Chemotaxis was quantified as a percentage relative to that in
the vehicle control.
Cell stopper migration assay
Migration assay was performed using an Oris 96-well plate with Oris Cell
Seeding Stoppers (Platypus Technologies, CMA1.101) according to the
manufacturer’s instructions. A549 cells were seeded in DMEM plus 10%
FBS (105 cells/well) into an Oris 96-well plate containing Oris Cell Seeding
Stoppers and incubated for 18 h (37°C/5% CO2) to allow attachment.
Following incubation, stoppers were removed and cells washed with 1×
PBS. The medium was replaced with DMEM plus 10% cFBS, and cells
were treated with 100 nM dex or vehicle control (DMSO). The cells were
incubated for 48 h to allowmigration into the detection zone to occur (37°C/
5% CO2). Reference wells had Oris Cell Seeding Stoppers left in place to act
as the no migration controls. Cells were washed with 1× PBS to remove any
debris/unattached cells, fixed in 4% PFA for 40 min at 4°C, and stained with
Hoechst 33342 (2 µg/ml; #14533; Sigma) for 5 min at room temperature to
label DNA. Images were collected on an Axio Observer A1 (Axiovision)
inverted microscope using a 2.5×/0.07 NA Plan-Apochromat objective and
captured using a Axio Cam HRc (Axiovision) through MetaVue Software
(Molecular Devices). Specific band pass filter sets for DAPI were used to
prevent bleed through from one channel to the next. Images were processed
and quantification of migration was achieved using ImageJ (http://rsb.info.
nih.gov/ij) (Schneider et al., 2012). Images were thresholded for high
intensities, converted into binary format, then analysed as particles to
determine the area of the detection zone covered with cells, using the no
migration controls for reference. Migration was then quantified as the
percentage of the detection zone covered with cells, relative to that of the
vehicle control.
Scratch wound healing assay
A549 cells were seeded in DMEM plus 10% cFBS (2×104 cells/well)
into a 96-well ImageLock plate (Essen Bioscience, #4379) and allowed
to adhere for 24 h (37°C/5% CO2). Simultaneous, uniform scratch
wounds were induced in each well with the WoundMaker tool (Essen
Bioscience) and wells were washed twice in DMEM plus 10% cFBS to
remove debris. Cell migration into the wound was acquired immediately
following administration of a dose response of dex, RU486 and
hydrocortisone (0.1 nM, 1 nM, 10 nM, 100 nM, 1 µM and 10 µM)
along with the vehicle control (DMSO). Images were taken at 30 min
intervals over 24 h (37°C/5% CO2) on an Incucyte Zoom Live-Cell
Analysis system using a 10×/0.3 NA Plan Fluor OFN25 (DIC L/N1)
objective in brightfield. Cell migration was analysed and quantified
using Incucyte Zoom software.
Live-cell brightfield migration
A549 cells were seeded in DMEM plus 10% cFBS (5×104 cells/well) into a
glass-bottomed 24-well plate (Greiner, #82050-898) and allowed to adhere
for 24 h (37°C and 5% CO2). Cell migration was monitored following
treatment with 100 nM dex, 100 nM RU486, 100 nM tubacin, 100 nM
086X, 3 nMGRT7 or vehicle control (DMSO) in real-time (37°C/5% CO2).
Images were captured over 24 h at intervals of 10 min on a Leica TCS SP5
AOBS inverted confocal using a 20×/0.5 NA Plan Fuotar objective in
brightfield. Cells were tracked using a wavelet plugin on IMARIS Pro Plus
software (MediaCybernetics) developed by Dr Egor Zindy (University of
Manchester, UK).
Transfection
Transfections were performed with Fugene 6 reagent (E2691; Promega)
used at a ratio of 3:1 volume-to-weight ratio with DNA. Fugene 6 was pre-
mixed with RPMI medium (serum-free) for 5 min prior to incubation with
DNA for 15 min at room temperature. Transfections were performed over
24 h at 37°C/5% CO2. Small interfering RNA (siRNA) transfections were
performed with Lipofectamine RNAiMAX reagent (#13778150;
ThermoFisher Scientific) as described in the manufacturer’s instructions
and performed over 48 h at 37°C/5% CO2.
Fig. 5. GC inhibits HDAC6 to regulate cell migration. (A) Representative
images of control and αTAT1-knockdown A549 cells stained via
immunofluorescence for αTAT1 (green) and F-actin (red). Nuclei were stained
with DAPI (blue). αTAT1-knockdown was siRNA mediated over 48 h,
alongside a non-silencing siRNA (ns siRNA) negative control. Images are
representative of three independent experiments. Widefield images were
acquired on a Delta Vision RT (Applied Precision, GE Healthcare) restoration
microscope at 20× magnification. (B) Cell migration data for A549 cells that
were tracked using brightfield microscopy. Cells were transiently transfected
with siRNA targeting αTAT1 or a non-targeting siRNA negative control for 48 h.
Images were acquired every 10 min, with data displaying all 24 h of tracking.
Violin plots of total displacement (µm) and median step length (µm) of control
and αTAT1 knockdown A549 cells in response to 24 h of vehicle and dex
(100 nM) treatment. Migration data shown as median±interquartile range
(IQR; dashed lines) and represents all cells analysed over two independent
experiments (Kruskal–Wallis non-parametric test followed by Dunn’s multiple
comparisons test; *P<0.003; ****P<0.0001). (C) Cell migration data for A549
cells that were tracked using brightfield microscopy. Images were acquired
every 10 min, with data displaying all 24 h of tracking. Violin plots of total
displacement (µm) and median step length (µm) of A549 cells in response to
24 h of vehicle, dex (100 nM), tubacin (100 nM), and dex plus tubacin (both
100 nM) co-treatment. Migration data shown as median±IQR and represents
all cells analysed over two independent experiments (Kruskal–Wallis non-
parametric test followed by Dunn’s multiple comparisons test; ****P<0.0001).
(D)Western blot of HDAC6 andGR protein expression in A549 cells transiently
transfected with pcDNA3.1 (empty vector control) or HDAC6–FLAG and
treated with 1 h of vehicle, dex (100 nM) or tubacin (100 nM). Western blot is
representative of two independent experiments. (E) Cell migration data for
A549 cells that were tracked using fluorescence microscopy based on GFP
expression. Cells were transiently co-transfected with H2B–GFP (0.25 µg) and
HDAC6–FLAG (0.25 µg) for 24 h. Cells were then treated with vehicle (DMSO)
or dex (100 nM), and images were acquired every 10 min for 24 h, with data
displaying 24 h of tracking. Violin plots of total displacement (µm) and median
step length (µm) of control (H2B–GFP) and HDAC6 overexpressing
(H2B–GFP+HDAC6–FLAG) A549 cells in response to 24 h of vehicle and dex
(100 nM) treatment. Migration data shown as median±IQR and represents all
cells analysed over two independent experiments (Kruskal–Wallis non-
parametric test followed by Dunn’s multiple comparisons test; ***P=0.0004,
****P<0.0001). (F) Frequency distribution curves of all A549 cell step lengths
(µm) in cells overexpressing empty control vector or HDAC6, in response to
vehicle and dex (100 nM) treatment. (G) Estimated mean±s.d. α-stable
distribution parameters of A549 cells overexpressing empty control vector or
HDAC6 in response to vehicle and dex (100 nM) treatment. α-Stable
parameters were derived by analysing experimentally determined step length
data in MATLAB. Parameters estimated were for media step length (µm),
stability exponent (α), skewness (β), scale (γ) and location (δ). Standard
deviation estimates were generated by parameterising 100 randomly sampled
subsets of the 15,000 values from the original data sets. (H) Probability density
function (PDF) plots of experimental step length data (black line) and PDF plots
generated from estimated α-stable distribution parameters (dark grey) in
response to vehicle and dex (100 nM) treatment. Plots generated in MATLAB.
(I) Cell migration data for A549 cells that were tracked using fluorescence
microscopy based onGFPexpression. Cells were treated with vehicle (DMSO)
or ITSA1 (5 µM) in combination with vehicle (DMSO), dex (100 nM) or RU486
(100 nM) for 24 h. Images were acquired every 10 min for 24 h, with data
displaying 24 h of tracking. Violin plots of total displacement (µm) and median
step length (µm) of A549 cells in response to 24 h vehicle, dex (100 nM),
RU486 (100 nM), ITSA1 (5 µM)+vehicle co-treatment, ITSA1 (5 µM)+dex
(100 nM) co-treatment, and ITSA1 (5 µM)+RU486 (100 nM) co-treatment.
Migration data shown as median±IQR and represents all cells analysed over
two independent experiments (Kruskal–Wallis non-parametric test followed by
Dunn’s multiple comparisons test; ****P<0.0001). ns, not significant.
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Live-cell immunofluorescence migration
A549 cells were seeded onto glass-bottomed 24-well plates (#662892;
Greiner) at 25,000 cells per well in DMEM plus 10% charcoal-stripped FBS
and left to adhere overnight. Cells were transiently transfected with 0.5 µg
pBOS-H2B-GFP and left to incubate for 24 h at 37°C/5% CO2. Cells were
treated with vehicle (DMSO) or dex (100 nM) and live-cell imaging was
Fig. 6. Activated GR and HDAC6 interact within the cytoplasm. (A) Confocal images of A549 cells co-transfected with HDAC6–eGFP and HaloTag–GR
treated or not with dex (100 nM) for 1 h. Confocal volumes designated for fluorescence cross-correlation spectroscopy (FCCS) measurements are indicated as
crosses (cytoplasm and nucleus). (B) Number of GR and HDAC6 molecules in response to vehicle and dex (100 nM) within the cytoplasm and nucleus.
(C) Relative cross-correlation (RCC) of the fraction of GR bound to HDAC6 (%) in response to vehicle and dex (100 nM) within the cytoplasm and nucleus. A549
cells expressing a fusion of EGFP and mCherry or separate free EGFP and mCherry were taken as positive and negative controls, respectively. *P=0.038
(matched-pairs one-way ANOVA followed by Sidak’s multiple comparison test). (D–F) Example autocorrelation curves of HDAC6 (green) and GR (red) in
response to vehicle and dex (100 nM) within the cytoplasm and example cross-correlation curves (blue) of HDAC6–GR interaction in response to vehicle and dex
within the cytoplasm. Solid and dotted lines represent raw and fitted correlation curves, respectively. (G–I) Binding kinetics of the HDAC6–GR interaction in
response to vehicle and dex (100 nM) within the cytoplasm. The fraction of the HDAC6–GR complex compared to total HDAC6–eGFP expressed was plotted
as a function of unbound HaloTag-GR and the equation ([complex]/[green]total)=([red]total−[complex])/(Kd+[red]total−[complex]) fit to determine the in vivo Kd
(orange line). (J) In vivo Kd of HDAC6–GR interaction in response to vehicle and dex (100 nM) within the cytoplasm. Kd displayed as mean with 95% c.i.
(for comparison of c.i. see Materials and Methods; +++P<0.001; ++++P<0.0001 indicates significant difference from negative control; **P<0.01). FCCS data
represent quantification of three independent experiments from >30 cells.
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performed for 48 h using a Nikon TE2000 PFS microscope. Images were
acquired every 5 min using a 20× Plan Apo objective and the Sedat filter set
(Chroma 89000). Cells were maintained at 37°C/5% CO2 throughout
imaging. The images were collected using a Coolsnap HQ (Photometrics,
USA) camera and raw images were processed using ImageJ.
RT2 profiler-PCR array
A human cell motility RT2 Profiler PCR array (384-well plate) was used to
assay gene expression changes following treatment (PAHS-128Z; Qiagen).
Cells were treated as required, then lysed and RNA extracted using an
RNeasy kit including the on-column DNase digestion step (#74104;
Qiagen). 400 ng RNA was reverse transcribed (#330401; Qiagen) and
cDNA samples were added to the reaction plate and real-time PCR acquired
using an ABI qPCR machine (Applied Biosystems, CA, USA). Cycle
threshold (CT) values were exported and analysed according to the
manufacturer’s instructions by RT2 profiler PCR array data analysis
software (http://dataanalysis.qiagen.com/pcr/arrayanalysis.php; Qiagen).
Five housekeeping genes were assessed and the most suitable, RPLP0,
was selected for normalisation of gene expression. A complete data set is
provided in Table S1, presented as a fold change over the vehicle control and
95% confidence interval for each gene analysed.
Quantitative RT-PCR
A549 cells were treated as required, then lysed and RNA extracted using an
RNeasy kit including the on-column DNase digestion step to remove
genomic DNA (#74104; Qiagen). 1 µg of RNA was reverse transcribed
(#4387406; Applied Biosystems) and analysed by qPCR using Sybr Green
detection. Gene expression was assessed using the following primer pairs:
glyceraldehyde-3-phosphate dehydrogenase (GAPDH), forward primer,
5′-GAAGGTGAAGGTCGGAGT-3′, reverse primer, 5′-CATGGGTGG-
AATCATATTGGAA-3′; TSC22D3, forward primer, 5′-TGTGGATGAG-
GGATGAACAA-3′, reverse primer, 5′-ACCCGCTACAGACAAGCTTT-
3′; FK506 binding protein 5 (FKBP5), forward primer, 5′-TGTCTCCCA-
CGTGTGTATTAT-3′, reverse primer, 5′-TTTGCTCAGAACCACTCAC-
AC-3′; pyruvate dehydrogenase kinase 4 (PDK4), forward primer,
5′-CGGGATCAAAGTGGGTCTAC-3′, reverse primer, 5′-GGAGGAAA-
CAAGGGTTCACA-3′. Data were analysed by the ΔΔCT method and
normalised to GAPDH.
Immunoblot analysis
Cells were treated as described in the results and lysed on ice for 30 min with
modified RIPA buffer (50 mM Tris-HCl pH 7.4, 1% NP-40, 0.25% sodium
deoxycholate, 150 mM NaCl, 1 mM EDTA) supplemented with protease
inhibitor (#04693124001, Roche) and phosphatase inhibitor cocktails
(P5726; P0044; Sigma). Cell lysates were scraped into 1.5 ml Eppendorf
tubes, cleared by centrifugation at 14,000 g for 10 min at 4°C. Supernatants
were collected and protein concentration determined by Bradford assay
#23236; Thermo Fisher Scientific. Lysates were resuspended to 1 mg/mL in
1× Laemmli buffer (0.125 M Tris-HCl pH 6.8, 0.1% SDS, 20% glycerol,
0.2% β-mercaptoethanol and 0.001% Bromophenol Blue) and boiled at
95°C for 10 min. Lysates were electrophoresed on Tris-glycine (4-20%)
Mini-PROTEAN TGX precast polyacrylamide protein gels (15-well, 15 µl
per lane) (#4561096, BioRad, Hertfordshire, UK) using 1× Tris-glycine
running buffer (#1610732; BioRad) and run at 130 V for 60 min at room
temperature. Gels were transferred onto nitrocellulose membranes using
transfer buffer (192 mM glycine, 25 mM Tris base, 20% methanol) and run
at 90 V for 60 min at 4°C. Membranes were blocked in blocking buffer (2%
skimmed milk, 150 µM NaCl and 0.1% Tween-20) for 2 h at room
temperature and incubated with relevant primary antibodies diluted in
blocking buffer overnight at 4°C. Membranes were washed 3× in wash
buffer (0.3% milk, 48 mM Tris-HCl pH 7.6, 24.8 mM Tris base, 0.1%
Tween-20) for 10 min and incubated with relevant horseradish peroxidase
(HRP)-tagged secondary antibodies diluted (1:5000) in wash buffer for 1 h
at room temperature. Membranes were washed three times in wash buffer
and exposed to enhanced chemiluminescence (ECL) Clarity reagent
(#1705060; BioRad) for 2 min. Protein bands were visualised using
BioMax MR photographic film (#V8572786; GE Healthcare).
HaloTag pulldown assay
A549 cells were seeded onto 15 cm2 dishes at 300,000 cells per ml in CSM
and left to incubate for 24 h at 37°C/5% CO2. Cells were transiently
transfected with either HaloTag-GR (10 µg) or HaloTag-HDAC6 (10 µg)
and left to incubate for 24 h. Cells were treated with vehicle (DMSO) or dex
(100 nM) for 1 h and washed twice with ice-cold 1× PBS. Cells were gently
scraped into conical tubes and centrifuged at 2000 g for 10 min at 4°C.
Supernatant was discarded and cell pellets were stored overnight at −80°C
prior to lysis. Before cell lysis, HaloTag resin (G1912; Promega) was mixed
to obtain uniform suspension and 200 µl resin was dispensed into 1.5 mL
Eppendorf tubes per treatment condition. Tubes were centrifuged at 800 g
for 1 min, supernatant discarded, and resuspended in 800 µl resin
equilibration buffer (100 mM Tris-HCl, 150 mM NaCl, 0.005% IGEPAL
CA-630). Tubes were centrifuged at 800 g for 2 min and supernatant
discarded. Resin was washed an additional 3× in equilibration buffer. Cell
pellets were thawed on ice and resuspended in 300 µl lysis buffer (50 mM
Tris-HCl pH 7.5, 150 mM NaCl, 1% Triton X-100, 0.1% sodium
deoxycholate) supplemented with 6 µl of 50× protease inhibitor cocktail
(800 µg/ml benzamidine HCl, 500 µg/ml phenanthroline, 500 µg/ml
aprotinin, 500 µg/ml leupeptin, 500 µg/ml pepstatin A and 50 mM
PMSF). Cells were passed five times through a 25G needle to complete
lysis and centrifuged at 14,000 g for 5 min at 4°C. Cleared lysates (300 µl)
were transferred to new 1.5 ml tubes and diluted in 700 µl 1× TBS (100 mM
Tris-HCl pH 7.5 and 150 mM NaCl). 1 ml diluted lysates were mixed with
the washed HaloTag resin and left to incubate overnight on a tube rotator at
4°C. Tubes were centrifuged at 800 g for 2 min and supernatant discarded.
Pellets were washed four times in resin equilibration buffer. After the last
wash, resin was resuspended.
Luciferase reporter gene assay
HeLa cells were seeded onto 10 cm2 dishes at 50,000 cells per well in CSM
and left to adhere overnight. Cells were transiently transfected with
luciferase tagged-mouse mammary tumour virus (MMTV-Luc; 2 µg) or
luciferase tagged-nuclear factor-κB response element (NRE-Luc; 2 µg)
using Fugene 6 reagent (3:1 volume-to-weight ratio with DNA) for 24 h.
Cells were re-seeded onto 24-well plates at 50,000 cells per well in CSM and
left to adhere overnight at 37°C/5% CO2. Cells were treated as specified in
the results, and 18 h later each well was washed twice with 1× PBS. 100 µl
of Bright Glo lysis buffer (Promega, E2620) was added to each well and left
to lyse on ice for 30 min. Cell lysates were transferred to a white, flat-
bottomed 96-well plate and luciferase absorbance was read using a
luminometer (Glomax, Promega). Ten 1-s reads were taken from each well
and the average relative light units (RLUs) determined. Background wells
were included that only contained lysis buffer. IC50 and EC50 values were
extrapolated from the resulting dose–response curves using non-linear
regression analysis in GraphPad Prism software, with the following
equation: Y=Bottom+{Top-Bottom)/[1+10^(LogIC50-X)×HillSlope]}.
Where X, log of dose or concentration; Y, response; Top and Bottom,
plateaus; LogIC50 interchangeable with LogEC50; HillSlope, slope factor or
Hill slope, unitless.
Fixed-cell immunofluorescence imaging
A549 cells were seeded in DMEM plus 10% cFBS (5×104 cells per
coverslip) and allowed to adhere for 24 h (37°C/5%CO2). Cells were treated
with vehicle or dex (100 nM) for 48 h. Cells were fixed with 4% PFA for
40 min at 4°C and blocked (0.1% Triton X-100, 1% FBS in PBS) for 1 h at
room temperature. The remaining incubations were performed at room
temperature unless stated otherwise. Coverslips were incubated with
primary antibody diluted in blocking buffer overnight at 4°C. After three
5 min washes in PBS, coverslips were incubated with flourophore-
conjugated secondary antibody for 2 h. Cells were subsequently stained
with rhodamine-phalloidin in PBS (2 µg/ml) for 15 min and then Hoechst
33342 in PBS (2 µg/ml) for 5 min. Following four 5 min washes in PBS,
coverslips were mounted using Vectamount AQ (Vector Labs, H-5501).
Images were acquired on a Delta Vision RT (Applied Precision, GE
Healthcare) restoration microscope using either a 40×/0.85 NA Uplan Apo
objective or a 60×/1.42 NA Plan Apo N objective and the Sedat Quad filter
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set (Chroma 86000v2, VT, USA). The images were collected using a
Coolsnap HQ (Photometrics, AZ, USA) camera with a Z optical spacing of
0.5 μm. Raw images were then deconvolved using the Softworx software
(GE Healthcare) and maximum intensity projections of these deconvolved
images processed using ImageJ.
Live-cell imaging
GR trafficking
A549 cells were seeded in DMEMcontaining cFBS (2.5×104cells/well) into
a glass-bottomed 24-well plate (Greiner, #82050-898) and allowed to adhere
for 24 h at 37°C/5% CO2. Each well was co-transfected (Fugene 6) with
0.25 µg HaloTag-GR (Promega, FHC10483) and 0.25 µg pBOS-H2B-GFP
(BD Biosciences, Oxford, UK) and, 6 h later, incubated for 16 h with
0.25 µl Halo ligand (HaloTag TMRDirect, G2991, Promega) to enable
HaloTag visualisation. Alternately, wells were transfected with 0.5 µg
HaloTag-HDAC6 (Promega, Southampton, UK) and incubated for 16 h
with 0.25 µl HaloTag TMR Direct ligand (Promega, G2991). Sub-cellular
GR/HDAC6 trafficking was tracked in real-time at 37°C and 5% CO2.
Images were acquired on a Nikon TE2000 PFS microscope using a 20× Plan
Apo objective and the Sedat filter set (Chroma 89000). The images were
collected using a Coolsnap HQ (Photometrics, USA) camera and raw
images were processed using ImageJ.
Fluorescence cross-correlation spectroscopy
A549 cells were seeded onto glass bottomed 35 mm dishes (#627965;
Greiner) at 25,000 cells per well in CSM and left to adhere overnight. Cells
were transiently co-transfected with HaloTag-GR (500 ng) and HDAC6-
eGFP (500 ng) using Fugene 6 reagent (3:1 v/w ratio with DNA) for 24 h.
At 6 h post-transfection, cells were treated with 100 nM HaloTMR Direct
ligand (G2991; Promega) overnight to visualise HaloTag-GR. The
following morning, cells were washed once with CSM before being
treated with GC. FCCS was performed using either a Zeiss LSM780 or
LSM880 equipped with GaAsP detectors using a plan-apochromat 63×/1.4
NA oil objective. EGFP was excited with 488 nm (0.3%) laser light and
emission collected between 500 and 530 nm. Rhodamine–mCherry was
excited with 561 nm (0.3%) laser light and emission collected between 580
and 630 nm. Single-point 5×5 s runs FCCS measurements were taken
within the cytoplasm and nucleus of individual cells. Zen 2.3 software was
used for data collection and correlation-curve fitting. A two-component 3D
diffusion model using a fixed structural parameter (S=4) with or without
triplet states were fitted for autocorrelation and cross-correlation curves,
respectively. FCCS measurements were rejected if counts per molecule
(CPM) were <1 kHz, or if they exhibited >10% photobleaching in either the
green or red channels. Structural parameter values of 4 and an effective
confocal volume size of 0.57 fL were previously measured allowing for
determination of molar concentrations (Schneider et al., 2012). The ‘fit’ and
‘confit’ functions in MATLAB 2018a were used to determine in vivo
dissociation constants and confidence intervals according to the equation
(Costes et al., 2004):
complex½ 
eGFP–HDAC6½ total
¼ HaloTag–GR½ total  ½complex
Kd þ HaloTag–GR½ total  ½complex
:
Data points were excluded from the fit if total red or total green
concentrations were more than three standard deviations away from mean
values. Confidence intervals (0.95, 0.99, etc.) were compared to test for
statistical significance. FCCS data represent quantification of three
independent experiments from >30 cells. Statistical significance of
relative cross-correlation (RCC) between HDAC6 and GR in vehicle- and
dex-treated A549 cells (within the cytoplasm and nucleus) was determined
using one-way ANOVA followed by Sidak’s multiple comparison testing
(P<0.05).
Live-cell microtubule dynamics
Microtubule dynamics were monitored in A549 cells transiently transfected
with 0.25 µg of EB3-GFP and 0.75 µg pcDNA3 using Fugene 6 reagent and
treating with vehicle or dex (100 nM) for 4 h prior to imaging. Cells were
selected at random based on the expression of EB3–GFP and images were
captured every 0.5 s for 1 min on a Nikon TE2000 PFS microscope using an
apo-TIRF 100×/1.49 NA oil objective. The images were collected using a
Cascade II EMCCD camera (Photometrics) with a Z optical spacing of
0.2 μm. Raw images were then processed using Image J (Schneider et al.,
2012).
Image analysis
For live-cell pBOS-H2B-GFP tracking, A549 cell movement was tracked
using the ImageJ plugin Mosaic based on pBOS-H2B-GFP expression.
Tracking was performed following the manufacturer’s instructions.
Co-ordinates of the tracks and the corresponding movies including tracks
were exported, from which step length, the distance moved between each
image acquisition, and total displacement, the overall distance each cell
moved where calculated. For step length, the median step length for each cell
was calculated over the duration of tracking and then displayed graphically
or a frequency distribution curve of all step lengths from every cell was
generated.
Rose-plots were created from 20 cells chosen at random to be displayed as
a rose plot. Co-ordinates were transformed so every cell track originated
from the XY co-ordinates (0,0). Rose plots were generated in GraphPad
Prism.
Co-localisation of HDAC6 with actin or tubulin was determined by using
ImarisColoc software (Bitplane), which utilises the algorithms developed by
Costes et al. (2004) to automate co-localisation.
Mathematical analysis
Frequency distributions of step lengths were parameterised and fitted to
alpha stable distribution using the STBL: Alpha stable distributions
functions package for MATLAB (available at https://www.mathworks.
com/matlabcentral/fileexchange/37514-stbl-alpha-stable-distributions-for-
matlab). The parameters estimated were for media step length (µm), stability
exponent (α), skewness (β), scale (γ) and location (δ). A standard
resampling strategy was used to validate the parameters. Random
sampling with replacement from the original data sets was performed to
generate 100 subsets of 15,000 values. These subsets were then
parameterised according to an α-stable distribution to derive robust
estimates of the standard deviations. The functions package was used to
calculate probability distribution functions (PDFs) of the empirical data and
from the determined parameters, and plot them on the same axis.
Live-cell brightfield tracking
A549 cell movement was tracked using Imaris 8.0 software (Media
Cybernetics, ltd). Migration was tracked using an autoregressive motion
algorithm from cells filtered by size (25 µm) and from tracks filtered by
minimum movement speed (above 2.5 µm/minute) to discount stationary
debris. Cell migration was depicted as step length between each time point,
which was determined using Pythagoras (square root of a2+b2=c, where a is
the position along the x-axis, b is the position along the y- axis, and c is the
step length).
Analysis of EB3 tracking
A MATLAB-based software package, plusTipTracker (https://omictools.
com/plustiptracker-tool) (Applegate et al., 2011; Matov et al., 2010), was
used to determine microtubule dynamics (growth, shrinkage and pausing
events) from EB3 time-lapse movies. All movies were analysed with the
following parameter values, which were determined prior to analysis using
the plusTipParamSweepGUI tool within plusTipTracker: maximum gap
length, 10 frames; minimum track length, 3 frames; search radius range,
5–10 pixels; maximum forward angle, 20°; maximum backward angle, 10°;
maximum shrinkage factor, 1; fluctuation radius, 1.5 pixel. The
plusTipGetTracks tool was used to detect and track fluorescently labelled
MT plus-end-binding proteins (+TIPs), with only MT growth events being
detected in both vehicle and dex treated cells. Overlay images showing the
tracks for MT growth speed were generated with the plusTipSeeTracks tool.
Raw data was collected from the gs_fs_bs_gl_fl_bl_gd_fd_bd.txt generated
by the plusTipGetTracks tool and combined; the frequency of comet growth
speeds were determined. Data was subdivided into slow, medium, fast and
very fast comets and histograms were generated in GraphPad Prism.
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Statistical analysis of cell movement data
Cumulative distance data for varying-length trajectories (∼1000 cells in
each experiment, measurements every 10 min up to 24 h) for cells treated
with GW870086X, dexamethasone, GRT7, and RU486 were used to
perform statistical test on the median reduction in cumulative distance
travelled against corresponding vehicle-treated cells.
For any pair, for example dexamethasone versus vehicle, and at each time
point, two distributions of cumulative distances are compared using a non-
parametric rank-sum test (using MATLAB), reporting significance (at
α=0.0001) of median reduction under treatment (e.g. dexamethasone) with
respect to vehicle against the null hypothesis that medians are equal in both
distributions.
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